Business Wire

NY-GCN

Share
Giga Carbon Neutrality Inc., the Global Leader in Providing Open V2X Systems and Commercial Transportation Clean Energy Solutions, Secures USD500 Million SSF Capital Commitment From GEM

Giga Carbon Neutrality Inc. (“GCN”) today announced a USD500 Million capital commitment from GEM Global Yield LLC SCS ("GEM"), the Luxembourg based private alternative investment group, in the form of a Share Subscription Facility (“SSF”). Under the agreement, GEM will provide GCN with a Share Subscription Facility of up to USD 500 Million of GCN’s common stock.

Martin Wade, Chairman of GCN, commented: “The world is embracing rapid industrial transformation brought about by new energy systems and their integration into various industry sectors. GCN has strong and comprehensive technical expertise in commercial vehicles and equipment. With its intelligent V2X (vehicle-connected-to-everything) technology and its smart IoT (internet of things) systems, GCN is a pioneer committed to becoming a total solution provider including vehicle equipment manufacturing, comprehensive technologies, operation platforms, energy data and carbon credit services. The SSF provided by GEM demonstrates investors’ confidence in GCN’s prospects and the company’s ability to build out its leading status as a provider of intelligent new energy commercial solutions. The SSF will allow us to finance cutting-edge technology capabilities and substantial expansion of service platform and sales.”

About GCN

GCN, together with its affiliates, provides solutions of new energy commercial vehicle equipment and comprehensive services to clients globally. GCN acts as a service and product integrator in the global intelligent commercial transportation and equipment market to efficiently realize customers’ carbon neutrality goals. GCN and its partners offer vehicle equipment manufacturing, comprehensive technologies, operation platforms, energy data and carbon credit services. For more information, please visit the website: https://gigacarbonneutrality.com/

About GEM

Global Emerging Markets (“GEM”) is a Luxembourg based private alternative investment group with offices in Paris, New York and The Bahamas. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 525 transactions in 72 countries. Each investment vehicle has a different degree of operational controls, risk-adjusted returns, and liquidity profiles. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments.

For more information: http://www.gemny.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005455/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans13.5.2025 08:00:00 CEST | Press release

TreeFrog Therapeutics is the first company to present publicly a clinical-ready delivery strategy for 3D format microtissues in cell therapy.After four years in development, the validated device and delivery strategy overcomes challenges of 3D formats and uses existing stereotactic components to support adoption through ease of delivery education. TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic re

Ohana Development Launches ‘Jacob & Co. Beachfront Living by Ohana,’ A Masterpiece of Beachfront Elegance in the UAE13.5.2025 08:00:00 CEST | Press release

Valued at USD 1.3 billion, the project offers world-class amenities, including a signature Jacob & Co. ceiling art timepiece, the largest of its kind globally. Ohana Development, the leading real estate developer renowned for its luxury properties, has launched ‘Jacob & Co. Beachfront Living by Ohana’ in partnership with luxury timepiece and jewellery house Jacob & Co. The project was revealed at Emirates Palace Mandarin Oriental, Abu Dhabi. Located in Al Jurf between Dubai and Abu Dhabi, this USD 1.3 billion development blends natural surroundings with exceptional artistry and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512533615/en/ Jacob & Co. Beachfront Living by Ohana. (Photo: AETOSWire) Jacob & Co. Beachfront Living by Ohana presents 457 residences comprising of sea-view apartments, villas, penthouses, Sky Mansions, and beachfront mansions—each capturing the spirit of refined coastal living. Pentho

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders13.5.2025 07:00:00 CEST | Press release

Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investorsProceeds to fund two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses as well as expanding the Azafaros pipeline to other indicationsNizubaglustat has been awarded Orphan Drug Designation in both the US and Europe as well as Fast-track status in the US. The company expects to initiate both Phase 3 studies later this year Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of an oversubscribed €132M Series B financing led by Jeito Capital, co-led by Forbion Growth and with additional participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV). This financing enables Az

Presidio Investors is Pleased to Announce the Addition of Christian Schütte as Its Newest Operating Partner12.5.2025 19:04:00 CEST | Press release

Christian brings more than 20 years of global experience in investment banking, private equity, and operational leadership, with a proven track record of driving transformational growth across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512473756/en/ Christian Schütte Christian began his career at J.P. Morgan in New York and London, where he worked in the M&A and Corporate Finance teams. He later joined Fortress Investment Group and was instrumental in launching its German operations. During his tenure, he helped raise over €1.5 billion in equity and managed a wide array of investments, including non-performing and performing loans, private and public companies. He went on to join EQT Group, where he focused on mid-market growth and succession investments. Notably, he led the consolidation of nine digital marketing agencies into a €100 million market leader, building one of the most comprehensive digital ma

Introducing Joblio – The Future of Ethical Recruitment12.5.2025 18:30:00 CEST | Press release

Joblio Launches to Revolutionize Ethical Recruitment and End Worker Exploitation Joblio, a global ethical recruitment platform, officially launches today to tackle the broken labor migration system—long plagued by exploitative intermediaries, high recruitment fees, and human rights abuses. With its tech-driven model, Joblio connects vetted workers with employers directly, eliminating unethical middlemen and ensuring cost-free hiring for migrant workers. Employers fund access to talent, but workers never pay—a key step in ending exploitation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512628048/en/ A Mission Rooted in Personal Experience Joblio is led by Jon Purizhansky, a refugee-turned-entrepreneur who experienced migration challenges firsthand. Forced to flee his home country as a young man, Jon faced the uncertainty and vulnerability that millions of migrant workers still encounter today. Now a globally recognized

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye